China's Pharmaceutical Industry 15th Five-Year Plan, Reported 18 September 2026, Lists Quantum Computing for Drug R&D; the 2021 Plan Did Not
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 18 September 2026 Chinese business media reported that the Ministry of Industry and Information Technology and nine other central departments had issued a five-year plan for the pharmaceutical industry that lists quantum computing among the technologies the state wants applied to drug research. The predecessor plan of December 2021 listed artificial intelligence, cloud computing and big data for the same job, and the word quantum did not appear in its published text.
The underlying document, which this Monitor knows through the reports of it rather than from the notice itself, is the 15th Five-Year Plan for the pharmaceutical industry, filed as MIIT joint planning document 2026 number 210 and covering 2026 to 2030. In its passage on frontier technologies, as quoted by the business press, it asks industry, universities, research institutes and hospitals to speed up the use of artificial intelligence, quantum computing, supercomputing and computational medicine in drug research and development. The same plan sets a target that Chinese first-in-class drugs make up at least 25 percent of the global total by 2030.
A planning document is a statement of intent, not a result. For a reader who buys for a hospital or runs a pharmaceutical research group in Europe, its value lies in what it tells you about where Chinese public money, procurement and regulatory attention will go for the rest of the decade, and in the gap between the plan's language and the evidence a physicist in Shanghai asked the same industry to produce a week earlier.
The ten signatories are the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Natural Resources, the Ministry of Agriculture and Rural Affairs, the Ministry of Commerce, the National Health Commission, the Ministry of Emergency Management, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine and the National Medical Products Administration.
Lu Chaoyang Called "Quantum New Drugs" a Packaged Product at the 2026 Bund Summit; Califano Calls Cancer "Quantum" as an Analogy
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
In September 2026 the word "quantum" reached medicine from two directions, and the contrast is instructive for anyone who buys for a hospital or a drug company. In Shanghai, the physicist Lu Chaoyang told the 2026 Bund Summit that some Chinese companies sell "quantum new drugs" as finished products while leading research teams still offer prize money for a practical quantum algorithm. In New York, Columbia University published a feature on 26 August in which the cancer biologist Andrea Califano called cancer a "quantum disease", a comparison with electron energy levels and no quantum hardware in it.
Califano's phrase points at two Nature Genetics papers, a pancreatic cancer dataset of hundreds of thousands of single cells, and a testable count of six cell states. The quantum new drugs that Lu Chaoyang objected to are described in a Xinmin Evening News commentary of 11 September as marketing, and the commentary supplies no product-level evidence for a buyer to assess. It also asked why the correction had to come from a scientist and why no industry regulator has set a standard for what a company may call quantum. That is the question a buyer should put to a vendor before any contract is signed.
NEO, the First Approved Implantable BCI, and the NSCEB's Gap List of 2 September 2026: What China Has in Place, What the US Lacks, and a 1,951-Character Mandarin Claim With No Located Paper
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A person with a cervical spinal cord injury can imagine closing a hand for years without the hand moving. The brain still issues the command; the spinal cord no longer carries it. A brain-computer interface reads the command above the break and sends it to a machine that does the closing. Regulatory approval, manufacturing capacity and reimbursement all decide whether such a device reaches routine care, and this week the two largest medical markets showed how differently they handle the three.
On 13 March 2026 China's National Medical Products Administration granted market approval to NEO, an implantable brain-computer interface for hand motor function developed by Neuracle, known in Chinese as Boruikang, with Tsinghua University. On 2 September 2026 the US National Security Commission on Emerging Biotechnology published an analysis that called it the world's first commercial approval of an implanted BCI and listed four missing US mechanisms. The same week brought a Chinese magazine profile claiming 1,951 Chinese characters decoded from an implant, and a Taiwanese report on a US company that wants to read the brain through the nose. This Monitor reads the cluster for what each item can support.